Alpha Tau Medical (NASDAQ:DRTS) Shares Down 2% – What’s Next?

Shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS) were down 2% during trading on Friday . The stock traded as low as $4.30 and last traded at $4.31. Approximately 27,766 shares were traded during trading, a decline of 56% from the average daily volume of 62,805 shares. The stock had previously closed at $4.40.

Analyst Ratings Changes

DRTS has been the subject of several analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alpha Tau Medical in a research report on Saturday, September 27th. HC Wainwright reiterated a “buy” rating and set a $9.00 price target on shares of Alpha Tau Medical in a report on Wednesday, September 3rd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $9.00.

Alpha Tau Medical Trading Down 2.0%

The company has a quick ratio of 5.81, a current ratio of 10.52 and a debt-to-equity ratio of 0.07. The business has a 50-day simple moving average of $3.57 and a 200-day simple moving average of $3.10. The company has a market cap of $365.57 million, a PE ratio of -8.98 and a beta of 1.07.

Alpha Tau Medical (NASDAQ:DRTS) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). On average, analysts predict that Alpha Tau Medical Ltd. will post -0.45 EPS for the current fiscal year.

Institutional Trading of Alpha Tau Medical

An institutional investor recently raised its position in Alpha Tau Medical stock. Kovitz Investment Group Partners LLC lifted its holdings in Alpha Tau Medical Ltd. (NASDAQ:DRTS) by 601.4% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 226,320 shares of the company’s stock after purchasing an additional 194,055 shares during the period. Kovitz Investment Group Partners LLC owned approximately 0.32% of Alpha Tau Medical worth $568,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 2.65% of the company’s stock.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.